Each biomarker sensor converts a concentration into a fractional activation through a Hill function; the AND-gate promoter only fires when both sensors are active, multiplying the two fractions together. That gate output drives the production rate of a therapeutic protein, which is continuously cleared by a tunable degradation-tag rate — so the payload level settles at a steady state set by the balance of promoter strength and degradation, not by either alone. If output crosses the kill-switch threshold (a burden/toxicity limit) the safety circuit engages and shuts transcription down until levels fall back under control.
gate = (A^n / (Ka^n + A^n)) * (B^n / (Kb^n + B^n))
dP/dt = β · gate − δ · P (production − degradation)
kill-switch: if P ≥ threshold → β → 0 until P relaxes
- Marker A / B — the two disease biomarkers the circuit must detect simultaneously (e.g. tumor-surface antigens); an AND gate needs both above their sensor thresholds before the promoter turns on, which is what gives the circuit tumor-specificity instead of firing on either signal alone.
- Promoter strength (β) — maximum transcription rate once the gate is fully open; raising it makes the therapeutic output rise faster and settle higher.
- Degradation rate (δ) — how fast a protein-degradation tag clears the payload; raising it lowers the steady-state output and makes the circuit respond and reset faster, a classic speed-vs-amplitude tradeoff in circuit design.
- Kill-switch threshold — the safety ceiling: cross it and the circuit self-shuts to avoid toxic overexpression, then re-arms once output falls back under the line.
Real-world relevance: this AND-gate sense-and-respond architecture is the core design pattern behind experimental cell therapies that must recognize a specific disease signature before releasing a therapeutic payload, minimizing off-target activity while still needing a hard safety cutoff for unexpected overexpression.